Plasma 3-0-methyldopa in L-dopa therapy of Parkinson's disease
Muenter, M.D.; Sharpless, N.S.; Tyce, G.M.
Mayo Clinic Proceedings 47(6): 389-395
1972
ISSN/ISBN: 0025-6196 PMID: 5041685 Document Number: 44402
Document emailed within 1 workday
Related Documents
Muenter, M.D.; Tyce, G.M. 1971: L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects Mayo Clinic Proceedings 46(4): 231-239Glasgow, G.L.; Henley, J.W.; Willoughby, E.W. 1974: L-alpha-methyldopa hydrazine (Carbidopa) combined with L-dopa in the treatment of Parkinson's disease Australian and New Zealand Journal of Medicine 4(4): 373-378
Routh, J.I.; Bannow, R.E.; Fincham, R.W.; Stoll, J.L. 1971: Excretion of L-dopa and its metabolites in urine of Parkinson's disease patients receiving L-dopa therapy Clinical Chemistry 17(9): 867-871
Indo, T.; Takahashi, A. 1987: Should L-dopa therapy for Parkinson's disease be started early or late? Clinical course of the major tetrad in 122 Parkinsonian patients treated with L-dopa over 14 years Rinsho Shinkeigaku 27(11): 1419-1422
Petit, H. 1984: Early or late dopa therapy in Parkinson's disease Presse Medicale 13(36): 2213
Del Dotto, P.; Colzi, A.; Pardini, C.; Lucetti, C.; Dubini, A.; Grimaldi, R.; Bonuccelli, U. 1995: Cabergoline improves motor disability without modifying L-dopa plasma levels in fluctuating Parkinson's disease patients Journal of Neural Transmission. Supplementum 45: 259-265
Broussolle, E. 2000: Dopa-therapy in the treatment of early stage Parkinson's disease Revue Neurologique (Paris) 156(2 Part 2): 91-97
Gauthier, G.; de Ajuriaguerra, J.; Geissbuhler, F.; Simona, B.; Constantinidis, J.; Yanniotis, G.; Krassoievitch, M.; Eisenring, J.J.; Tissot, R. 1971: Substitutive therapy in Parkinson's syndromes. L-dopa plus peripheral decarboxylase inhibitor or 3-0-methyl dopa? La Presse Medicale 79(3): 91-92
Selby, G. 1976: The influence of previous stereotactic thalamotomy on l-dopa therapy in Parkinson's disease Proceedings of the Australian Association of Neurologists 13: 55-60
Lipman, I.J.; Papadopoulos, N.M. 1973: Cerebrospinal fluid N-acetyl neuraminic acid in Parkinson's disease, before and after L-dopa therapy Diseases of the Nervous System 34(1): 59-62
Fuchs, G. 1997: Parkinson disease--problems in long-term treatment. Dopamine agonists optimize L-dopa therapy Fortschritte der Medizin 115(5): 43-45
Yahr, M.D.; Duvoisin, R.C.; Mendoza, M.R.; Schear, M.J.; Barrett, R.E. 1971: Modification of L-dopa therapy of Parkinsonism by alpha-methyldopa hydrazine (MK-486) Transactions of the American Neurological Association 96: 55-58
Christiani, K.; Möller, W.D. 1973: Drug therapy of Parkinson's syndrome. Clinical long-term study using L-dopa and the drug conbination L-dopa-decarboxylase inhibitor Münchener Medizinische Wochenschrift 115(16): 711-713
Sweet, R.D.; Lee, J.E.; McDowell, F. 1971: Alpha-methyldopa as an adjunct to levodopa treatment of Parkinson's disease Transactions of the American Neurological Association 96: 59-65
Lees, A.J. 1986: L-dopa treatment and Parkinson's disease Quarterly Journal of Medicine 59(230): 535-547
Dalle Ore, G.; Bricolo, A.; Robotti, E.; Bazzan, A.; Mazza, C. 1970: The treatment of Parkinson's disease with L-dopa Il Policlinico. Sezione Pratica 77(16): 509-524
Völler, G. 1970: L-dopa in the treatment of Parkinson's disease Die Medizinische Welt 27: 1267-1268
Ginath, Y.; Lavy, S.; Abramsky, O.; Carmon, A. 1971: Mental complications of L-dopa therapy in Parkinson's patients Israel Annals of Psychiatry and Related Disciplines 9(3): 252-264
Pendefunda, G.; Pollingher, B.; Stefanache, F.; Gavril, A.; Oprisan, C.; Merling, M.; Nemteanu, E.; Ciunru, M.; Koropitzer, I. 1975: The treatment with L-dopa and amantadine in Parkinson's disease Therapia Hungarica 23(1): 12-16
Henry, P.; Lacut, J.Y.; Pouget-Abadie, J.; Bergouignan, M.; Leng-Lĕvy, J. 1971: One year of experience with L-Dopa in Parkinson's disease Bordeaux Medical 4(5): 1581-1591